EULAR recommendations for the management of antiphospholipid syndrome in adults

Annals of the Rheumatic Diseases

Volumn 78, Issue 10, 2019, Pages 1296-1304

  Tektonidou, Maria G ^a   Andreoli, Laura ^b   Limper, Marteen ^c   Amoura, Zahir ^d   Cervera, Ricard ^e   Costedoat Chalumeau, Nathalie ^f   Cuadrado, Maria Jose ^g   Dörner, Thomas ^h   Ferrer Oliveras, Raquel ⁱ   Hambly, Karen ^j   Khamashta, Munther A ^k   King, Judith ^l   Marchiori, Francesca ^m   Meroni, Pier Luigi ⁿ   Mosca, Marta ^o   Pengo, Vittorio ^p   Raio, Luigi ^q   Ruiz Irastorza, Guillermo ^r   Shoenfeld, Yehuda ^s   Stojanovich, Ljudmila ^t   Svenungsson, Elisabet ^u   Wahl, Denis ^v   Tincani, Angela ^b   Ward, Michael M ^w   more..

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d SORBONNE UNIVERSITÉ   (France)

^e UNIVERSITY OF BARCELONA   (Spain)

^f CRESS ^*  (France)

^g UNIVERSITY CLINIC OF NAVARRA   (Spain)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ VALL D'HEBRON INSTITUTE OF ONCOLOGY   (Spain)

^j UNIVERSITY OF KENT   (United Kingdom)

^k DUBAI HOSPITAL   (United Arab Emirates)

^l EULAR PARE Patient Research Partner   (United Kingdom)

^m Patient Research Partner ADIPSO PEPsoPOF   (Italy)

ⁿ ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^o UNIVERSITY OF PISA   (Italy)

^p UNIVERSITY OF PADOVA   (Italy)

^q UNIVERSITY OF BERN   (Switzerland)

^r HOSPITAL DE CRUCES   (Spain)

^s TEL AVIV UNIVERSITY   (Israel)

^t UNIVERSITY OF BELGRADE   (Serbia)

^u KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^v UNIVERSITY HOSPITAL OF NANCY   (France)

^w NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

more..

Author keywords

antiphospholipid antibodies; antiphospholipid syndrome; management; pregnancy morbidity; recommendations; systemic lupus erythematosus; thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; HYDROXYCHLOROQUINE; LOW MOLECULAR WEIGHT HEPARIN; PHOSPHOLIPID ANTIBODY; PREDNISOLONE; ANTICOAGULANT AGENT;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; CARDIOVASCULAR RISK; COUNSELING; EVIDENCE BASED MEDICINE; HIGH RISK POPULATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIFESTYLE; LOW DRUG DOSE; PATIENT COMPLIANCE; PATIENT EDUCATION; PREGNANCY; PRIORITY JOURNAL; PROPHYLAXIS; SCREENING; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC LUPUS ERYTHEMATOSUS; VEIN THROMBOSIS; BLOOD; FEMALE; IMMUNOLOGY; MALE; PRACTICE GUIDELINE; PREGNANCY COMPLICATION; RHEUMATOLOGY; RISK FACTOR;

ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PREGNANCY COMPLICATIONS; RHEUMATOLOGY; RISK FACTORS; VENOUS THROMBOSIS;

EID: 85065986415     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2019-215213     Document Type: Article

References (69)

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classifcation criteria for defnite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
2. Cervera R, Serrano R, Pons-Estel GJ, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2015;74:1011-8.
3. Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task Force at the 13th International Congress on antiphospholipid antibodies. Lupus 2011;20:206-18.
4. Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med 2018;378:2010-21.
5. Van der Heijde D, Aletaha D, Carmona L, et al. 2014 update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Ann Rheum Dis 2015;74:8-13.
6. Brouwers MC, Kho ME, Browman G P, et al. Agree II: advancing Guideline Development, reporting and evaluation in health care. CMAJ 2010;182:E83 9-E842.
7. Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018;132:1365-71.
8. OCEBM Levels of Evidence Working Group. The Oxford levels of evidence 2: Oxford centre for evidence-based medicine. Available: Error! Hyperlink reference not valid.
9. Tektonidou MG, Andreoli L, Limper M, et al. Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review Informing the EULAR recommendations for the management of antiphospholipid syndrome in adults. RMD Open.
10. Chighizola CB, Andreoli L, Gerosa M, et al. The treatment of anti-phospholipid syndrome: a comprehensive clinical approach. J Autoimmun 2018;90:1-27.
11. Otomo K, Atsumi T, Amengual O, et al. Effcacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum 2012;64:504-12.
12. Sciascia S, Sanna G, Murru V, et al. Gapss: the global anti-phospholipid syndrome score. Rheumatology 2013;52:1397-403.
13. Andreoli L, Bertsias GK, Agmon-Levin N, et al. Eular recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis 2017;76:476-85.
14. Arnaud L, Mathian A, Ruffatti A, et al. Effcacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. Autoimmun Rev 2014;13:281-91.
15. Arnaud L, Mathian A, Devilliers H, et al. Patient-level analysis of fve international cohorts further confrms the effcacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. Autoimmun Rev 2015;14:192-200.
16. Tarr T, Lakos G, Bhattoa H P, et al. Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients. Lupus 2007;16:39-45.
17. Tektonidou MG, Laskari K, Panagiotakos DB, et al. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 2009;61:29-36.
18. Erkan D, Merrill JT, Yazici Y, et al. High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin. Arthritis Rheum 2001;44:1466-7.
19. Forastiero R, Martinuzzo M, Pombo G, et al. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost 2005;3:1231-8.
20. Ruffatti A, Del Ross T, Ciprian M, et al. Risk factors for a frst thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis 2011;70:1083-6.
21. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003;349:1133-8.
22. Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin VS. Conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005;3:848-53.
23. Rosove MH, Brewer PM. Antiphospholipid thrombosis: clinical course after the frst thrombotic event in 70 patients. Ann Intern Med 1992;117:303-8.
24. Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995;332:993-7.
25. Ames PRJ, Ciampa A, Margaglione M, et al. Bleeding and re-thrombosis in primary antiphospholipid syndrome on oral anticoagulation: an 8-year longitudinal comparison with mitral valve replacement and inherited thrombophilia. Thromb Haemost 2005;93:694-9.
26. ®, RE-COVER™ II, And RE-MEDY™. Vasc Med 2016;21:506-14.
27. Cohen H, Hunt BJ, Efthymiou M, et al. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol 2016;3:e426-36.
28. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med 1998;104:332-8.
29. Ginsberg JS, Wells PS, Brill-Edwards P, et al. Antiphospholipid Antibodies and venous thromboembolism. Blood 1995;86:3685-91.
30. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTe disease: chest guideline and expert panel report. Chest 2016;149:315-52.
31. Verro P, Levine SR, Tietjen GE. Cerebrovascular ischemic events with high positive anticardiolipin antibodies. Stroke 1998;29:2245-53.
32. Wang C-R, Liu M-F. Rituximab usage in systemic lupus erythematosus-associated antiphospholipid syndrome: a single-center experience. Semin Arthritis Rheum 2016;46:102-8.
33. Levine SR, Brey RL, Tilley BC, et al. Antiphospholipid Antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004;291:576-84.
34. Tektonidou MG, Ioannidis J P, Boki KA, et al. Prognostic factors and clustering of serious clinical outcomes in antiphospholipid syndrome. QJM 2000;93:523-30.
35. Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum 2007;57:1487-95.
36. Krnic-Barrie S, O'Connor CR, Looney SW, et al. A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors infuencing recurrent thrombosis. Arch Intern Med 1997;157:2101-8.
37. Okuma H, Kitagawa Y, Yasuda T, et al. Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome. Int J Med Sci 2009;7:15-18.
38. Dufrost V, Risse J, Reshetnyak T, et al. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis. Autoimmun Rev 2018;17:1011-21.
39. Uthman I, Noureldine MHA, Ruiz-Irastorza G, et al. Management of antiphospholipid syndrome. Ann Rheum Dis 2019;78:155-61.
40. Erkan D, Unlu O, Sciascia S, et al. Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease. Lupus 2018;27:399-406.
41. Andrade D, Tektonidou M. Emerging therapies in antiphospholipid syndrome. Curr Rheumatol Rep 2016;18.
42. Kaaja R, Julkunen H, Viinikka L, et al. Production of prostacyclin and thromboxane in lupus pregnancies: effect of Small dose of aspirin. Obstet Gynecol 1993;81:229-31.
43. Cowchock S, Reece EA. Do low-risk pregnant women with antiphospholipid antibodies need to be treated? organizing group of the antiphospholipid antibody treatment trial. Am J Obstet Gynecol 1997;176:1099-100.
44. Kahwa EK, Sargeant LA, McCaw-Binns A, et al. Anticardiolipin antibodies in Jamaican primiparae. J Obstet Gynaecol 2006;26:122-6.
45. Del Ross T, Ruffatti A, Visentin MS, et al. Treatment of 139 pregnancies in antiphospholipid-positive women not fulflling criteria for antiphospholipid syndrome: a retrospective study. J Rheumatol 2013;40:425-9.
46. Rai R, Cohen H, Dave M, et al. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997;314:253-7.
47. Lima F, Khamashta MA, Buchanan NM, et al. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol 1996;14:131-6.
48. Muñoz-Rodriguez FJ, Font J, Cervera R, et al. Clinical study and follow-up of 100 patients with the antiphospholipid syndrome. Semin Arthritis Rheum 1999;29:182-90.
49. Naru T, Khan RS, Ali R. Pregnancy outcome in women with antiphospholipid syndrome on low-dose aspirin and heparin: a retrospective study. East Mediterr Health J 2010;16:308-12.
50. Cohn DM, Goddijn M, Middeldorp S, et al. Recurrent miscarriage and antiphospholipid antibodies: prognosis of subsequent pregnancy. J Thromb Haemost 2010;8:2208-13.
51. Mohamed KAA, Saad AS. Enoxaparin and aspirin therapy for recurrent pregnancy loss due to anti-phospholipid syndrome (APS). Middle East Fertil Soc J 2014;19:176-82.
52. Ruffatti A, Salvan E, Del Ross T, et al. Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. a European multicentre retrospective study. Thromb Haemost 2014;112:727-35.
53. Franklin RD, Kutteh WH. Antiphospholipid antibodies (APA) and recurrent pregnancy loss: treating a unique APA positive population. Hum Reprod 2002;17:2981-5.
54. Laskin CA, Spitzer KA, Clark CA, et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA trial. J Rheumatol 2009;36:279-87.
55. Van Hoorn ME, Hague WM, Van Pampus MG, et al. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. Eur J Obstet Gynecol Reprod Biol 2016;197:168-73.
56. Mekinian A, Lazzaroni MG, Kuzenko A, et al. The effcacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: data from a European multicenter retrospective study. Autoimmun Rev 2015;14:498-502.
57. Bramham K, Thomas M, Nelson-Piercy C, et al. First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss. Blood 2011;117:6948-51.
58. Diejomaoh M F, Al-Azemi MM, Bandar A, et al. A favorable outcome of pregnancies in women with primary and secondary recurrent pregnancy loss associated with antiphospholipid syndrome. Arch Gynecol Obstet 2002;266:61-6.
59. Jeremic K, Pervulov M, Gojnic M, et al. Comparison of two therapeutic protocols in patients with antiphospholipid Antibodies and recurrent miscarriages. Vojnosanit Pregl 2005;62:435-9.
60. Heilmann L, Schorch M, Hahn T, et al. Pregnancy outcome in women with antiphospholipid antibodies: report on a retrospective study. Semin Thromb Hemost 2008;34:794-802.
61. Stone S, Hunt BJ, Khamashta MA, et al. Primary antiphospholipid syndrome in pregnancy: an analysis of outcome in a cohort of 33 women treated with a rigorous protocol. J Thromb Haemost 2005;3:243-5.
62. Bramham K, Hunt BJ, Germain S, et al. Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome. Lupus 2010;19:58-64.
63. Fischer-Betz R, Specker C, Brinks R, et al. Pregnancy outcome in patients with antiphospholipid syndrome after cerebral ischaemic events: an observational study. Lupus 2012;21:1183-9.
64. Saccone G, Berghella V, Maruotti GM, et al. Antiphospholipid antibody profle based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study. Am J Obstet Gynecol 2017;216:525.e1-525.e12.
65. De Jesús GR, Sciascia S, Andrade D, et al. Factors associated with frst thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for clinical trials and international networking clinical database and Repository: a retrospective study. BJOG 2019;126.
66. Bates SM, Middeldorp S, Rodger M, et al. Guidance for the treatment and prevention of obstetric-associated venous thromboembolism. J Thromb Thrombolysis 2016;41:92-128.
67. Cervera R, Rodríguez-Pintó I, Colafrancesco S, et al. 14Th International Congress on antiphospholipid antibodies Task Force report on catastrophic antiphospholipid syndrome. Autoimmun Rev 2014;13:699-707.
68. Cervera R, Tektonidou MG, Espinosa G, et al. Task Force on catastrophic antiphospholipid syndrome (APS) and Non-criteria APS manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions. Lupus 2011;20:165-73.
69. Legault K, Schunemann H, Hillis C, et al. Mcmaster RARE-Best practices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome. J Thromb Haemost 201810.1111/jth.14192. [Epub ahead of print: 07 Jun 2018].